{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:23:08Z","timestamp":1776770588653,"version":"3.51.2"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41585-024-00991-8","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T13:00:57Z","timestamp":1737032457000},"page":"447-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prostate cancer epigenetics \u2014 from pathophysiology to clinical application"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-0367","authenticated-orcid":false,"given":"Vera","family":"Const\u00e2ncio","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-3347","authenticated-orcid":false,"given":"Jos\u00e9 Pedro","family":"Sequeira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"991_CR1","unstructured":"Ferlay J. et al. International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today https:\/\/gco.iarc.who.int\/today (accessed 29 June 2014)."},{"key":"991_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MC Wong","year":"2016","unstructured":"Wong, M. C. et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur. Urol. 70, 862\u2013874 (2016).","journal-title":"Eur. Urol."},{"key":"991_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","volume":"71","author":"GW Dy","year":"2017","unstructured":"Dy, G. W., Gore, J. L., Forouzanfar, M. H., Naghavi, M. & Fitzmaurice, C. Global burden of urologic cancers, 1990\u20132013. Eur. Urol. 71, 437\u2013446 (2017).","journal-title":"Eur. Urol."},{"key":"991_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson, J. et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur. Urol. 76, 43\u201351 (2019).","journal-title":"Eur. Urol."},{"key":"991_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nrurol.2016.90","volume":"13","author":"A Auvinen","year":"2016","unstructured":"Auvinen, A. Prudent practice optimizes screening outcomes. Nat. Rev. Urol. 13, 376\u2013377 (2016).","journal-title":"Nat. Rev. Urol."},{"key":"991_CR6","unstructured":"The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015)."},{"key":"991_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1056\/NEJMra021562","volume":"349","author":"WG Nelson","year":"2003","unstructured":"Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Mechanisms of disease: prostate cancer. N. Engl. J. Med. 349, 366\u2013381 (2003).","journal-title":"N. Engl. J. Med."},{"key":"991_CR8","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.21037\/tau-20-1339","volume":"10","author":"V Conteduca","year":"2021","unstructured":"Conteduca, V., Hess, J., Yamada, Y., Ku, S. Y. & Beltran, H. Epigenetics in prostate cancer: clinical implications. Transl. Androl. Urol. 10, 3104\u20133116 (2021).","journal-title":"Transl. Androl. Urol."},{"key":"991_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.eururo.2011.06.035","volume":"60","author":"C Jer\u00f3nimo","year":"2011","unstructured":"Jer\u00f3nimo, C. et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 60, 753\u2013766 (2011).","journal-title":"Eur. Urol."},{"key":"991_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41586-019-1411-0","volume":"571","author":"G Cavalli","year":"2019","unstructured":"Cavalli, G. & Heard, E. Advances in epigenetics link genetics to the environment and disease. Nature 571, 489\u2013499 (2019).","journal-title":"Nature"},{"key":"991_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33932-3","volume":"13","author":"N Besselink","year":"2023","unstructured":"Besselink, N. et al. The genome-wide mutational consequences of DNA hypomethylation. Sci. Rep. 13, 6874 (2023).","journal-title":"Sci. Rep."},{"key":"991_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu, X. et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 10, 28 (2024).","journal-title":"Cell Death Discov."},{"key":"991_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2017.99","volume":"18","author":"E Anastasiadou","year":"2018","unstructured":"Anastasiadou, E., Jacob, L. S. & Slack, F. J. Non-coding RNA networks in cancer. Nat. Rev. Cancer 18, 5\u201318 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"991_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-015-0076-2","volume":"7","author":"P Costa-Pinheiro","year":"2015","unstructured":"Costa-Pinheiro, P. et al. MicroRNA-375 plays a dual role in prostate carcinogenesis. Clin. Epigenetics 7, 42 (2015).","journal-title":"Clin. Epigenetics"},{"key":"991_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10555-016-9628-y","volume":"35","author":"J Ramalho-Carvalho","year":"2016","unstructured":"Ramalho-Carvalho, J., Fromm, B., Henrique, R. & Jeronimo, C. Deciphering the function of non-coding RNAs in prostate cancer. Cancer Metastasis Rev. 35, 235\u2013262 (2016).","journal-title":"Cancer Metastasis Rev."},{"key":"991_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41568-021-00357-x","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao, S., Allis, C. D. & Wang, G. G. The language of chromatin modification in human cancers. Nat. Rev. Cancer 21, 413\u2013430 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"991_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrurol.2010.185","volume":"7","author":"AS Perry","year":"2010","unstructured":"Perry, A. S., Watson, R. W., Lawler, M. & Hollywood, D. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol. 7, 668\u2013680 (2010).","journal-title":"Nat. Rev. Urol."},{"key":"991_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0264-8","volume":"8","author":"I Graca","year":"2016","unstructured":"Graca, I. et al. Epigenetic modulators as therapeutic targets in prostate cancer. Clin. Epigenetics 8, 98 (2016).","journal-title":"Clin. Epigenetics"},{"key":"991_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","volume":"75","author":"M L\u00f8vf","year":"2019","unstructured":"L\u00f8vf, M. et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur. Urol. 75, 498\u2013505 (2019).","journal-title":"Eur. Urol."},{"key":"991_CR20","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/ng.3315","volume":"47","author":"PC Boutros","year":"2015","unstructured":"Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736\u2013745 (2015).","journal-title":"Nat. Genet."},{"key":"991_CR21","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3221","volume":"47","author":"CS Cooper","year":"2015","unstructured":"Cooper, C. S. et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 47, 367\u2013372 (2015).","journal-title":"Nat. Genet."},{"key":"991_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27615-8","volume":"12","author":"SE Eksi","year":"2021","unstructured":"Eksi, S. E. et al. Epigenetic loss of heterogeneity from low to high grade localized prostate tumours. Nat. Commun. 12, 7292 (2021).","journal-title":"Nat. Commun."},{"key":"991_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645\u2013661 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"991_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0540-x","volume":"10","author":"TM Storebjerg","year":"2018","unstructured":"Storebjerg, T. M. et al. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. Clin. Epigenetics 10, 105 (2018).","journal-title":"Clin. Epigenetics"},{"key":"991_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24380-6","volume":"12","author":"M Zoma","year":"2021","unstructured":"Zoma, M. et al. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer. Nat. Commun. 12, 4147 (2021).","journal-title":"Nat. Commun."},{"key":"991_CR26","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","volume":"19","author":"A Urbanucci","year":"2017","unstructured":"Urbanucci, A. et al. Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer. Cell Rep. 19, 2045\u20132059 (2017).","journal-title":"Cell Rep."},{"key":"991_CR27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nm.4378","volume":"23","author":"X Dai","year":"2017","unstructured":"Dai, X. et al. Prostate cancer\u2013associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Med. 23, 1063\u20131071 (2017).","journal-title":"Nat. Med."},{"key":"991_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","volume":"23","author":"P Zhang","year":"2017","unstructured":"Zhang, P. et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT\u2013mTORC1 activation. Nat. Med. 23, 1055\u20131062 (2017).","journal-title":"Nat. Med."},{"key":"991_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35135-2","volume":"13","author":"J Kneppers","year":"2022","unstructured":"Kneppers, J. et al. Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential. Nat. Commun. 13, 7367 (2022).","journal-title":"Nat. Commun."},{"key":"991_CR30","doi-asserted-by":"publisher","first-page":"R267","DOI":"10.1530\/ERC-19-0032","volume":"26","author":"S Stelloo","year":"2019","unstructured":"Stelloo, S., Bergman, A. M. & Zwart, W. Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers. Endocr. Relat. Cancer 26, R267\u2013R285 (2019).","journal-title":"Endocr. Relat. Cancer"},{"key":"991_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-3-031-11836-4_15","volume":"1390","author":"J Kneppers","year":"2022","unstructured":"Kneppers, J., Bergman, A. M. & Zwart, W. Prostate cancer epigenetic plasticity and enhancer heterogeneity: molecular causes, consequences and clinical implications. Adv. Exp. Med. Biol. 1390, 255\u2013275 (2022).","journal-title":"Adv. Exp. Med. Biol."},{"key":"991_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s13148-011-0041-7","volume":"2","author":"SP Chin","year":"2011","unstructured":"Chin, S. P., Dickinson, J. L. & Holloway, A. F. Epigenetic regulation of prostate cancer. Clin. Epigenetics 2, 151\u2013169 (2011).","journal-title":"Clin. Epigenetics"},{"key":"991_CR33","doi-asserted-by":"crossref","unstructured":"Henrique, R. & Jer\u00f3nimo, C. GSTP1 hypermethylation for prostate cancer detection. Prostate Cancer Screening 279\u2013288 (2009).","DOI":"10.1007\/978-1-60327-281-0_19"},{"key":"991_CR34","doi-asserted-by":"publisher","first-page":"11733","DOI":"10.1073\/pnas.91.24.11733","volume":"91","author":"WH Lee","year":"1994","unstructured":"Lee, W. H. et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91, 11733\u201311737 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"991_CR35","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/jnci\/93.22.1747","volume":"93","author":"C Jeronimo","year":"2001","unstructured":"Jeronimo, C. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747\u20131752 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"991_CR36","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2004.06.014","volume":"46","author":"R Henrique","year":"2004","unstructured":"Henrique, R. & Jer\u00f3nimo, C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur. Urol. 46, 660\u2013669 (2004).","journal-title":"Eur. Urol."},{"key":"991_CR37","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/ijc.11227","volume":"106","author":"M Yamanaka","year":"2003","unstructured":"Yamanaka, M. et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer 106, 382\u2013387 (2003).","journal-title":"Int. J. Cancer"},{"key":"991_CR38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2174\/138920211797904061","volume":"12","author":"S Majumdar","year":"2011","unstructured":"Majumdar, S., Buckles, E., Estrada, J. & Koochekpour, S. Aberrant DNA methylation and prostate cancer. Curr. Genomics 12, 486\u2013505 (2011).","journal-title":"Curr. Genomics"},{"key":"991_CR39","doi-asserted-by":"publisher","first-page":"8472","DOI":"10.1158\/1078-0432.CCR-04-0894","volume":"10","author":"C Jeronimo","year":"2004","unstructured":"Jeronimo, C. et al. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 10, 8472\u20138478 (2004).","journal-title":"Clin. Cancer Res."},{"key":"991_CR40","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/pros.23895","volume":"79","author":"PG Patel","year":"2019","unstructured":"Patel, P. G. et al. A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. Prostate 79, 1705\u20131714 (2019).","journal-title":"Prostate"},{"key":"991_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3252-2","volume":"17","author":"MK Kirby","year":"2017","unstructured":"Kirby, M. K. et al. Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC Cancer 17, 1\u201310 (2017).","journal-title":"BMC Cancer"},{"key":"991_CR42","first-page":"175","volume":"7","author":"P Volkel","year":"2015","unstructured":"Volkel, P., Dupret, B., Le Bourhis, X. & Angrand, P. O. Diverse involvement of EZH2 in cancer epigenetics. Am. J. Transl. Res. 7, 175\u2013193 (2015).","journal-title":"Am. J. Transl. Res."},{"issue":"suppl. 7","key":"991_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/JCO.2019.37.7_suppl.94","volume":"37","author":"P Yonover","year":"2019","unstructured":"Yonover, P. et al. Clinical utility study of confirms mdx for prostate cancer in a community urology practice. J. Clin. Oncol. 37 (suppl. 7), Abstr. 94 (2019).","journal-title":"J. Clin. Oncol."},{"key":"991_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsbmb.2016.04.009","volume":"166","author":"CE Massie","year":"2017","unstructured":"Massie, C. E., Mills, I. G. & Lynch, A. G. The importance of DNA methylation in prostate cancer development. J. Steroid Biochem. Mol. Biol. 166, 1\u201315 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"991_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1593\/neo.13280","volume":"15","author":"B Yang","year":"2013","unstructured":"Yang, B. et al. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 15, 399\u2013408 (2013).","journal-title":"Neoplasia"},{"key":"991_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1541-7786.MCR-05-0113","volume":"4","author":"R Henrique","year":"2006","unstructured":"Henrique, R. et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol. Cancer Res. 4, 1\u20138 (2006).","journal-title":"Mol. Cancer Res."},{"key":"991_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91037-1","volume":"11","author":"MD Long","year":"2021","unstructured":"Long, M. D. et al. Dynamic patterns of DNA methylation in the normal prostate epithelial differentiation program are targets of aberrant methylation in prostate cancer. Sci. Rep. 11, 11405 (2021).","journal-title":"Sci. Rep."},{"key":"991_CR48","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/s41591-019-0579-z","volume":"25","author":"KE Houlahan","year":"2019","unstructured":"Houlahan, K. E. et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat. Med. 25, 1615\u20131626 (2019).","journal-title":"Nat. Med."},{"key":"991_CR49","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/2159-8290.CD-22-0027","volume":"12","author":"J Yuan","year":"2022","unstructured":"Yuan, J. et al. Prostate cancer transcriptomic regulation by the interplay of germline risk alleles, somatic mutations, and 3D genomic architecture. Cancer Discov. 12, 2838\u20132855 (2022).","journal-title":"Cancer Discov."},{"key":"991_CR50","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ccell.2018.10.016","volume":"34","author":"C Gerhauser","year":"2018","unstructured":"Gerhauser, C. et al. Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories. Cancer Cell 34, 996\u20131011.e1018 (2018).","journal-title":"Cancer Cell"},{"key":"991_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/andr.13258","volume":"11","author":"V Constancio","year":"2023","unstructured":"Constancio, V., Tavares, N. T., Henrique, R., Jeronimo, C. & Lobo, J. MiRNA biomarkers in cancers of the male reproductive system: are we approaching clinical application? Andrology 11, 651\u2013667 (2023).","journal-title":"Andrology"},{"key":"991_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2015.12.003","volume":"70","author":"R Mehra","year":"2016","unstructured":"Mehra, R. et al. Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur. Urol. 70, 549\u2013552 (2016).","journal-title":"Eur. Urol."},{"key":"991_CR53","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.omtn.2021.10.017","volume":"26","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Circular RNAs in prostate cancer: biogenesis, biological functions, and clinical significance. Mol. Ther. Nucleic Acids 26, 1130\u20131147 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"991_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48521-7","volume":"13","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Identification of differentially expressed circRNAs in prostate cancer of different clinical stages by RNA sequencing. Sci. Rep. 13, 21175 (2023).","journal-title":"Sci. Rep."},{"key":"991_CR55","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.7150\/thno.51931","volume":"11","author":"CW Pan","year":"2021","unstructured":"Pan, C. W. et al. Functional roles of antisense enhancer RNA for promoting prostate cancer progression. Theranostics 11, 1780\u20131794 (2021).","journal-title":"Theranostics"},{"key":"991_CR56","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/labinvest.3780190","volume":"80","author":"T Nakayama","year":"2000","unstructured":"Nakayama, T. et al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab. Invest. 80, 1789\u20131796 (2000).","journal-title":"Lab. Invest."},{"key":"991_CR57","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/onc.2016.376","volume":"36","author":"ML Nickerson","year":"2017","unstructured":"Nickerson, M. L. et al. TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene 36, 2172\u20132183 (2017).","journal-title":"Oncogene"},{"key":"991_CR58","volume":"6","author":"KI Takayama","year":"2015","unstructured":"Takayama, K. I. et al. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat. Commun. 6, 9219 (2015).","journal-title":"Nat. Commun."},{"key":"991_CR59","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/0008-5472.CAN-22-1123","volume":"82","author":"M Sjostrom","year":"2022","unstructured":"Sjostrom, M. et al. The 5-hydroxymethylcytosine landscape of prostate cancer. Cancer Res. 82, 3888\u20133902 (2022).","journal-title":"Cancer Res."},{"key":"991_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07270-2","volume":"9","author":"S Stelloo","year":"2018","unstructured":"Stelloo, S. et al. Integrative epigenetic taxonomy of primary prostate cancer. Nat. Commun. 9, 4900 (2018).","journal-title":"Nat. Commun."},{"key":"991_CR61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ccell.2019.03.001","volume":"35","author":"MA Augello","year":"2019","unstructured":"Augello, M. A. et al. CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell 35, 603\u2013617.e8 (2019).","journal-title":"Cancer Cell"},{"key":"991_CR62","doi-asserted-by":"publisher","first-page":"1123362","DOI":"10.3389\/fonc.2023.1123362","volume":"13","author":"H Li","year":"2023","unstructured":"Li, H., Gigi, L. & Zhao, D. CHD1, a multifaceted epigenetic remodeler in prostate cancer. Front. Oncol. 13, 1123362 (2023).","journal-title":"Front. Oncol."},{"key":"991_CR63","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-12-1342","volume":"73","author":"L Burkhardt","year":"2013","unstructured":"Burkhardt, L. et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 73, 2795\u20132805 (2013).","journal-title":"Cancer Res."},{"key":"991_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00705-8","volume":"8","author":"M Diossy","year":"2024","unstructured":"Diossy, M. et al. Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. NPJ Precis. Oncol. 8, 208 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"991_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","volume":"580","author":"J Li","year":"2020","unstructured":"Li, J. et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature 580, 93\u201399 (2020).","journal-title":"Nature"},{"key":"991_CR66","first-page":"PO.21.00324","volume":"5","author":"FR Schumacher","year":"2021","unstructured":"Schumacher, F. R. et al. Race and genetic alterations in prostate cancer. JCO Precis. Oncol. 5, PO.21.00324 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"991_CR67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/bjc.2015.234","volume":"113","author":"T Mitchell","year":"2015","unstructured":"Mitchell, T. & Neal, D. E. The genomic evolution of human prostate cancer. Br. J. Cancer 113, 193\u2013198 (2015).","journal-title":"Br. J. Cancer"},{"key":"991_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48629-y","volume":"15","author":"U Singhal","year":"2024","unstructured":"Singhal, U. et al. Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis. Nat. Commun. 15, 4341 (2024).","journal-title":"Nat. Commun."},{"key":"991_CR69","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/ijc.34226","volume":"152","author":"KT Carm","year":"2023","unstructured":"Carm, K. T. et al. Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer. Int. J. Cancer 152, 945\u2013951 (2023).","journal-title":"Int. J. Cancer"},{"key":"991_CR70","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","volume":"31","author":"R Ge","year":"2020","unstructured":"Ge, R. et al. Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann. Oncol. 31, 470\u2013479 (2020).","journal-title":"Ann. Oncol."},{"key":"991_CR71","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","volume":"52","author":"SG Zhao","year":"2020","unstructured":"Zhao, S. G. et al. The DNA methylation landscape of advanced prostate cancer. Nat. Genet. 52, 778\u2013789 (2020).","journal-title":"Nat. Genet."},{"key":"991_CR72","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/s41417-022-00492-z","volume":"29","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. CircRNA circ_0006156 inhibits the metastasis of prostate cancer by blocking the ubiquitination of S100A9. Cancer Gene Ther. 29, 1731\u20131741 (2022).","journal-title":"Cancer Gene Ther."},{"key":"991_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14270","volume":"8","author":"C Liu","year":"2017","unstructured":"Liu, C. et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat. Commun. 8, 14270 (2017).","journal-title":"Nat. Commun."},{"key":"991_CR74","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/bjc.2015.300","volume":"113","author":"Y Goto","year":"2015","unstructured":"Goto, Y. et al. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221\/222 cluster functions as a tumour suppressor and disease progression marker. Br. J. Cancer 113, 1055\u20131065 (2015).","journal-title":"Br. J. Cancer"},{"key":"991_CR75","doi-asserted-by":"publisher","first-page":"eabe1505","DOI":"10.1126\/science.abe1505","volume":"376","author":"F Tang","year":"2022","unstructured":"Tang, F. et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science 376, eabe1505 (2022).","journal-title":"Science"},{"key":"991_CR76","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar, T., Yang, J. C., Gao, A. C. & Evans, C. P. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl. Androl. Urol. 4, 365 (2015).","journal-title":"Transl. Androl. Urol."},{"key":"991_CR77","first-page":"3623","volume":"60","author":"H Kinoshita","year":"2000","unstructured":"Kinoshita, H. et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60, 3623\u20133630 (2000).","journal-title":"Cancer Res."},{"key":"991_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01119-0","volume":"13","author":"EB Ylitalo","year":"2021","unstructured":"Ylitalo, E. B. et al. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer. Clin. Epigenetics 13, 133 (2021).","journal-title":"Clin. Epigenetics"},{"key":"991_CR79","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","volume":"52","author":"MM Pomerantz","year":"2020","unstructured":"Pomerantz, M. M. et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat. Genet. 52, 790\u2013799 (2020).","journal-title":"Nat. Genet."},{"key":"991_CR80","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-17-0496","volume":"77","author":"Y Liang","year":"2017","unstructured":"Liang, Y. et al. LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression. Cancer Res. 77, 5479\u20135490 (2017).","journal-title":"Cancer Res."},{"key":"991_CR81","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","volume":"52","author":"S Gao","year":"2020","unstructured":"Gao, S. et al. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat. Genet. 52, 1011\u20131017 (2020).","journal-title":"Nat. Genet."},{"key":"991_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/jhg.2016.69","volume":"62","author":"S Kojima","year":"2017","unstructured":"Kojima, S., Goto, Y. & Naya, Y. The roles of microRNAs in the progression of castration-resistant prostate cancer. J. Hum. Genet. 62, 25\u201331 (2017).","journal-title":"J. Hum. Genet."},{"key":"991_CR83","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s12276-022-00837-6","volume":"54","author":"J Gan","year":"2022","unstructured":"Gan, J. et al. MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4\/STAT3 axis. Exp. Mol. Med. 54, 1290\u20131305 (2022).","journal-title":"Exp. Mol. Med."},{"key":"991_CR84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114324119","volume":"119","author":"M Baratchian","year":"2022","unstructured":"Baratchian, M. et al. H3K9 methylation drives resistance to androgen receptor\u2013antagonist therapy in prostate cancer. Proc. Natl Acad. Sci. USA 119, e2114324119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"991_CR85","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41388-019-1116-8","volume":"39","author":"H Sara\u00e7","year":"2020","unstructured":"Sara\u00e7, H. et al. Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer. Oncogene 39, 2187\u20132201 (2020).","journal-title":"Oncogene"},{"key":"991_CR86","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","volume":"37","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation. Cancer Cell 37, 584\u2013598.e11 (2020).","journal-title":"Cancer Cell"},{"key":"991_CR87","first-page":"11623","volume":"47","author":"L Duan","year":"2019","unstructured":"Duan, L. et al. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation. Nucleic Acids Res. 47, 11623\u201311636 (2019).","journal-title":"Nucleic Acids Res."},{"key":"991_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38887-7","volume":"14","author":"T Nguyen","year":"2023","unstructured":"Nguyen, T. et al. Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer. Nat. Commun. 14, 3357 (2023).","journal-title":"Nat. Commun."},{"key":"991_CR89","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41594-019-0219-9","volume":"26","author":"E Metzger","year":"2019","unstructured":"Metzger, E. et al. KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nat. Struct. Mol. Biol. 26, 361\u2013371 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"991_CR90","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.celrep.2016.03.038","volume":"15","author":"Y Zhao","year":"2016","unstructured":"Zhao, Y. et al. Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in castration-resistant prostate cancer. Cell Rep. 15, 599\u2013610 (2016).","journal-title":"Cell Rep."},{"key":"991_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37075","volume":"10","author":"Y Yao","year":"2024","unstructured":"Yao, Y. et al. Extrachromosomal circular DNA-related SPOCK1 contributes to development and enzalutamide resistance of prostate cancer by regulating epithelial mesenchymal transition. Heliyon 10, e37075 (2024).","journal-title":"Heliyon"},{"key":"991_CR92","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.trecan.2022.04.011","volume":"8","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Gong, L. & Wei, C. L. Guilt by association: EcDNA as a mobile transactivator in cancer. Trends Cancer 8, 747\u2013758 (2022).","journal-title":"Trends Cancer"},{"key":"991_CR93","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccell.2021.03.006","volume":"39","author":"Y Zhu","year":"2021","unstructured":"Zhu, Y. et al. Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription. Cancer Cell 39, 694\u2013707.e7 (2021).","journal-title":"Cancer Cell"},{"key":"991_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01111-8","volume":"13","author":"C Macedo-Silva","year":"2021","unstructured":"Macedo-Silva, C. et al. Epigenetic mechanisms underlying prostate cancer radioresistance. Clin. Epigenetics 13, 125 (2021).","journal-title":"Clin. Epigenetics"},{"key":"991_CR95","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/cncr.20093","volume":"100","author":"D Khuntia","year":"2004","unstructured":"Khuntia, D., Reddy, C. A., Mahadevan, A., Klein, E. A. & Kupelian, P. A. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1\u2013T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer 100, 1283\u20131292 (2004).","journal-title":"Cancer"},{"key":"991_CR96","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1158\/0008-5472.CAN-15-2116","volume":"76","author":"C Peitzsch","year":"2016","unstructured":"Peitzsch, C. et al. An epigenetic reprogramming strategy to resensitize radioresistant prostate cancer cells. Cancer Res. 76, 2637\u20132651 (2016).","journal-title":"Cancer Res."},{"key":"991_CR97","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrurol.2016.68","volume":"13","author":"L Stone","year":"2016","unstructured":"Stone, L. Prostate cancer: radiotherapy induces epigenetic changes. Nat. Rev. Urol. 13, 241 (2016).","journal-title":"Nat. Rev. Urol."},{"key":"991_CR98","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.celrep.2018.09.081","volume":"25","author":"J Bayo","year":"2018","unstructured":"Bayo, J. et al. Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks. Cell Rep. 25, 1040\u20131050.e5 (2018).","journal-title":"Cell Rep."},{"key":"991_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2405-4","volume":"11","author":"L Fan","year":"2020","unstructured":"Fan, L. et al. Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell Death Dis. 11, 214 (2020).","journal-title":"Cell Death Dis."},{"key":"991_CR100","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41392-023-01639-6","volume":"8","author":"C Macedo-Silva","year":"2023","unstructured":"Macedo-Silva, C. et al. Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling. Signal. Transduct. Target. Ther. 8, 395 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"991_CR101","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","volume":"22","author":"X Li","year":"2018","unstructured":"Li, X. et al. BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer. Cell Rep. 22, 796\u2013808 (2018).","journal-title":"Cell Rep."},{"key":"991_CR102","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1073\/pnas.1600420113","volume":"113","author":"K Komura","year":"2016","unstructured":"Komura, K. et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc. Natl Acad. Sci. USA 113, 6259\u20136264 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"991_CR103","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","volume":"39","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. p300\/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. Oncogene 39, 3939\u20133951 (2020).","journal-title":"Oncogene"},{"key":"991_CR104","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s42003-022-03843-6","volume":"5","author":"TS Rodems","year":"2022","unstructured":"Rodems, T. S. et al. Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. Commun. Biol. 5, 897 (2022).","journal-title":"Commun. Biol."},{"key":"991_CR105","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz, J. & Fong, L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 24, 697\u2013717 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"991_CR106","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1530\/ERC-19-0420","volume":"27","author":"A Davies","year":"2020","unstructured":"Davies, A., Zoubeidi, A. & Selth, L. A. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Endocr. Relat. Cancer 27, R35\u2013R50 (2020).","journal-title":"Endocr. Relat. Cancer"},{"key":"991_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36253-1","volume":"14","author":"G Chakraborty","year":"2023","unstructured":"Chakraborty, G., Gupta, K. & Kyprianou, N. Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer. Nat. Commun. 14, 567 (2023).","journal-title":"Nat. Commun."},{"key":"991_CR108","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305 (2016).","journal-title":"Nat. Med."},{"key":"991_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26042-z","volume":"12","author":"P Cejas","year":"2021","unstructured":"Cejas, P. et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat. Commun. 12, 5775 (2021).","journal-title":"Nat. Commun."},{"key":"991_CR110","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/JCI131041","volume":"130","author":"H Beltran","year":"2020","unstructured":"Beltran, H. et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J. Clin. Invest. 130, 1653\u20131668 (2020).","journal-title":"J. Clin. Invest."},{"key":"991_CR111","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624\u2013629 (2002).","journal-title":"Nature"},{"key":"991_CR112","doi-asserted-by":"publisher","first-page":"161.e7","DOI":"10.1016\/j.urolonc.2017.10.028","volume":"36","author":"J Lobo","year":"2018","unstructured":"Lobo, J. et al. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer. Urol. Oncol. 36, 161.e7\u2013161.e17 (2018).","journal-title":"Urol. Oncol."},{"key":"991_CR113","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916\u20136924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"991_CR114","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563\u2013577 (2016).","journal-title":"Cancer Cell"},{"key":"991_CR115","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"991_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19328-1","volume":"11","author":"J Cyrta","year":"2020","unstructured":"Cyrta, J. et al. Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity. Nat. Commun. 11, 5549 (2020).","journal-title":"Nat. Commun."},{"key":"991_CR117","first-page":"804","volume":"3","author":"T Akoto","year":"2020","unstructured":"Akoto, T., Bhagirath, D. & Saini, S. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer. Cancer Drug. Resist. 3, 804\u2013818 (2020).","journal-title":"Cancer Drug. Resist."},{"key":"991_CR118","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.3390\/s23177527","volume":"23","author":"YD Ivanov","year":"2023","unstructured":"Ivanov, Y. D. et al. Nanoribbon biosensor-based detection of microRNA markers of prostate cancer. Sensors 23, 7527 (2023).","journal-title":"Sensors"},{"key":"991_CR119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello, R. J. et al. Prostate cancer. Nat. Rev. Dis. Prim. 7, 9 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"991_CR120","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14737159.2019.1604224","volume":"19","author":"V Const\u00e2ncio","year":"2019","unstructured":"Const\u00e2ncio, V., Barros-Silva, D., Jer\u00f3nimo, C. & Henrique, R. Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies. Expert Rev. Mol. Diagn. 19, 367\u2013375 (2019).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"991_CR121","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.urolonc.2023.03.005","volume":"41","author":"R Ragavi","year":"2023","unstructured":"Ragavi, R. et al. Epigenetics regulation of prostate cancer: biomarker and therapeutic potential. Urol. Oncol. 41, 340\u2013353 (2023).","journal-title":"Urol. Oncol."},{"key":"991_CR122","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jncc.2022.09.002","volume":"2","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Zhang, M. & Wang, Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J. Natl Cancer Cent. 2, 277\u2013290 (2022).","journal-title":"J. Natl Cancer Cent."},{"key":"991_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18013-7","volume":"11","author":"R Vatapalli","year":"2020","unstructured":"Vatapalli, R. et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nat. Commun. 11, 4153 (2020).","journal-title":"Nat. Commun."},{"key":"991_CR124","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.celrep.2014.11.008","volume":"9","author":"C Cai","year":"2014","unstructured":"Cai, C. et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 9, 1618\u20131627 (2014).","journal-title":"Cell Rep."},{"key":"991_CR125","doi-asserted-by":"publisher","first-page":"E4584","DOI":"10.1073\/pnas.1802415115","volume":"115","author":"L Fan","year":"2018","unstructured":"Fan, L. et al. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proc. Natl Acad. Sci. USA 115, E4584\u2013E4593 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"991_CR126","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41588-021-00781-7","volume":"53","author":"DC Hargreaves","year":"2021","unstructured":"Hargreaves, D. C. Chromatin openness requires continuous SWI\/SNF activity. Nat. Genet. 53, 263\u2013264 (2021).","journal-title":"Nat. Genet."},{"key":"991_CR127","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.3390\/cancers13133325","volume":"13","author":"K Kukkonen","year":"2021","unstructured":"Kukkonen, K. et al. Chromatin and epigenetic dysregulation of prostate cancer development, progression, and therapeutic response. Cancers 13, 3325 (2021).","journal-title":"Cancers"},{"key":"991_CR128","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1172\/JCI123557","volume":"129","author":"Y Ding","year":"2019","unstructured":"Ding, Y. et al. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J. Clin. Invest. 129, 759\u2013773 (2019).","journal-title":"J. Clin. Invest."},{"key":"991_CR129","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02366494 (2024)."},{"key":"991_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02964351 (2016)."},{"key":"991_CR131","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03494803 (2023)."},{"key":"991_CR132","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03911999 (2021)."},{"key":"991_CR133","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04100811 (2023)."},{"key":"991_CR134","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05141383 (2024)."},{"key":"991_CR135","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05443412 (2024)."},{"key":"991_CR136","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3390\/ijms18092017","volume":"18","author":"M Norgaard","year":"2017","unstructured":"Norgaard, M. et al. Comprehensive evaluation of TFF3 promoter hypomethylation and molecular biomarker potential for prostate cancer diagnosis and prognosis. Int. J. Mol. Sci. 18, 2017 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"991_CR137","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00340717 (2008)."},{"key":"991_CR138","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0746-6","volume":"11","author":"V Fiano","year":"2019","unstructured":"Fiano, V. et al. DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer. Clin. Epigenetics 11, 152 (2019).","journal-title":"Clin. Epigenetics"},{"key":"991_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0779-x","volume":"11","author":"V Constancio","year":"2019","unstructured":"Constancio, V. et al. Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. Clin. Epigenetics 11, 175 (2019).","journal-title":"Clin. Epigenetics"},{"key":"991_CR140","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.juro.2012.08.219","volume":"189","author":"GD Stewart","year":"2013","unstructured":"Stewart, G. D. et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J. Urol. 189, 1110\u20131116 (2013).","journal-title":"J. Urol."},{"key":"991_CR141","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/1878-0261.12183","volume":"12","author":"C Haldrup","year":"2018","unstructured":"Haldrup, C. et al. Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. Mol. Oncol. 12, 545\u2013560 (2018).","journal-title":"Mol. Oncol."},{"key":"991_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0771-5","volume":"11","author":"B Yang","year":"2019","unstructured":"Yang, B. et al. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. Clin. Epigenetics 11, 168 (2019).","journal-title":"Clin. Epigenetics"},{"key":"991_CR143","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","volume":"14","author":"GM Franceschini","year":"2024","unstructured":"Franceschini, G. M. et al. Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discov. 14, 424\u2013445 (2024).","journal-title":"Cancer Discov."},{"key":"991_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0575-z","volume":"10","author":"F Zhao","year":"2018","unstructured":"Zhao, F. et al. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clin. Epigenetics 10, 147 (2018).","journal-title":"Clin. Epigenetics"},{"key":"991_CR145","doi-asserted-by":"publisher","first-page":"10846","DOI":"10.3390\/ijms241310846","volume":"24","author":"A Aveta","year":"2023","unstructured":"Aveta, A. et al. Urinary MicroRNAs as biomarkers of urological cancers: a systematic review. Int. J. Mol. Sci. 24, 10846 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"991_CR146","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fgene.2019.00626","volume":"10","author":"M Cui","year":"2019","unstructured":"Cui, M. et al. Circulating microRNAs in cancer: potential and challenge. Front. Genet. 10, 626 (2019).","journal-title":"Front. Genet."},{"key":"991_CR147","doi-asserted-by":"publisher","first-page":"13890","DOI":"10.3390\/ijms241813890","volume":"24","author":"JP Sequeira","year":"2023","unstructured":"Sequeira, J. P. et al. OncoUroMiR: circulating miRNAs for detection and discrimination of the main urological cancers using a ddPCR-based approach. Int. J. Mol. Sci. 24, 13890 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"991_CR148","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3389\/fonc.2019.00900","volume":"9","author":"D Bidarra","year":"2019","unstructured":"Bidarra, D. et al. Circulating microRNAs as biomarkers for prostate cancer detection and metastasis development prediction. Front. Oncol. 9, 900 (2019).","journal-title":"Front. Oncol."},{"key":"991_CR149","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1158\/1078-0432.CCR-18-2849","volume":"25","author":"F Urabe","year":"2019","unstructured":"Urabe, F. et al. Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer. Clin. Cancer Res. 25, 3016\u20133025 (2019).","journal-title":"Clin. Cancer Res."},{"key":"991_CR150","doi-asserted-by":"publisher","first-page":"686","DOI":"10.21037\/tcr-23-1313","volume":"13","author":"C Sun","year":"2024","unstructured":"Sun, C. et al. The value of a panel of circulating microRNAs in screening prostate cancer. Transl. Cancer Res. 13, 686\u2013698 (2024).","journal-title":"Transl. Cancer Res."},{"key":"991_CR151","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1373\/clinchem.2018.296681","volume":"65","author":"J Freds\u00f8e","year":"2019","unstructured":"Freds\u00f8e, J. et al. Independent validation of a diagnostic noninvasive 3-microRNA ratio model (uCaP) for prostate cancer in cell-free urine. Clin. Chem. 65, 540\u2013548 (2019).","journal-title":"Clin. Chem."},{"key":"991_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50172-6","volume":"9","author":"M Barcelo","year":"2019","unstructured":"Barcelo, M., Castells, M., Bassas, L., Vigues, F. & Larriba, S. Semen miRNAs contained in exosomes as non-invasive biomarkers for prostate cancer diagnosis. Sci. Rep. 9, 13772 (2019).","journal-title":"Sci. Rep."},{"key":"991_CR153","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/JU.0000000000001020","volume":"204","author":"WW Wang","year":"2020","unstructured":"Wang, W. W. et al. Expression of small noncoding RNAs in urinary exosomes classifies prostate cancer into indolent and aggressive disease. J. Urol. 204, 466\u2013475 (2020).","journal-title":"J. Urol."},{"key":"991_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04661176 (2023)."},{"key":"991_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184094","volume":"12","author":"MF Souza","year":"2017","unstructured":"Souza, M. F. et al. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. PLoS ONE 12, e0184094 (2017).","journal-title":"PLoS ONE"},{"key":"991_CR156","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/JU.0000000000003507","volume":"210","author":"DM Berman","year":"2023","unstructured":"Berman, D. M. et al. Multimodal biomarkers that predict the presence of Gleason pattern 4: potential impact for active surveillance. J. Urol. 210, 257\u2013271 (2023).","journal-title":"J. Urol."},{"key":"991_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0716-z","volume":"11","author":"A Bakavicius","year":"2019","unstructured":"Bakavicius, A. et al. Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging. Clin. Epigenetics 11, 115 (2019).","journal-title":"Clin. Epigenetics"},{"key":"991_CR158","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","volume":"29","author":"SC Baca","year":"2023","unstructured":"Baca, S. C. et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat. Med. 29, 2737\u20132741 (2023).","journal-title":"Nat. Med."},{"key":"991_CR159","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3390\/cancers16071363","volume":"16","author":"JP Sequeira","year":"2024","unstructured":"Sequeira, J. P. et al. Biomarkers for pre-treatment risk stratification of prostate cancer patients: a systematic review. Cancers 16, 1363 (2024).","journal-title":"Cancers"},{"key":"991_CR160","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"GJ Van Leenders","year":"2020","unstructured":"Van Leenders, G. J. et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am. J. Surg. Pathol. 44, e87\u2013e99 (2020).","journal-title":"Am. J. Surg. Pathol."},{"key":"991_CR161","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1586\/14737159.2015.1110022","volume":"15","author":"CK Kontos","year":"2015","unstructured":"Kontos, C. K., Adamopoulos, P. G. & Scorilas, A. Prognostic and predictive biomarkers in prostate cancer. Expert Rev. Mol. Diagn. 15, 1567\u20131576 (2015).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"991_CR162","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.ajpath.2014.05.022","volume":"184","author":"J Stein","year":"2014","unstructured":"Stein, J. et al. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy. Am. J. Pathol. 184, 2430\u20132437 (2014).","journal-title":"Am. J. Pathol."},{"key":"991_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01201-7","volume":"13","author":"U Schagdarsurengin","year":"2021","unstructured":"Schagdarsurengin, U. et al. Tracing TET1 expression in prostate cancer: discovery of malignant cells with a distinct oncogenic signature. Clin. Epigenetics 13, 211 (2021).","journal-title":"Clin. Epigenetics"},{"key":"991_CR164","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/15592294.2016.1241931","volume":"11","author":"S Meller","year":"2016","unstructured":"Meller, S. et al. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics 11, 871\u2013880 (2016).","journal-title":"Epigenetics"},{"key":"991_CR165","doi-asserted-by":"publisher","first-page":"10030","DOI":"10.18632\/oncotarget.3192","volume":"6","author":"K Li","year":"2015","unstructured":"Li, K. et al. Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. Oncotarget 6, 10030\u201310044 (2015).","journal-title":"Oncotarget"},{"key":"991_CR166","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jmoldx.2016.08.008","volume":"19","author":"B Uhl","year":"2017","unstructured":"Uhl, B. et al. PITX2 DNA methylation as biomarker for individualized risk assessment of prostate cancer in core biopsies. J. Mol. Diagn. 19, 107\u2013114 (2017).","journal-title":"J. Mol. Diagn."},{"key":"991_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0742-x","volume":"11","author":"M Norgaard","year":"2019","unstructured":"Norgaard, M. et al. Epigenetic silencing of MEIS2 in prostate cancer recurrence. Clin. Epigenetics 11, 147 (2019).","journal-title":"Clin. Epigenetics"},{"key":"991_CR168","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/carcin\/bgx064","volume":"38","author":"Y Han","year":"2017","unstructured":"Han, Y., Xu, J., Kim, J., Wu, X. & Gu, J. Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients. Carcinogenesis 38, 821\u2013826 (2017).","journal-title":"Carcinogenesis"},{"key":"991_CR169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130651","volume":"10","author":"K Litovkin","year":"2015","unstructured":"Litovkin, K. et al. DNA methylation-guided prediction of clinical failure in high-risk prostate cancer. PLoS ONE 10, e0130651 (2015).","journal-title":"PLoS ONE"},{"key":"991_CR170","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1002\/ijc.32427","volume":"145","author":"SH Strand","year":"2019","unstructured":"Strand, S. H. et al. A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy. Int. J. Cancer 145, 3445\u20133452 (2019).","journal-title":"Int. J. Cancer"},{"key":"991_CR171","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/pros.23177","volume":"76","author":"RK Nam","year":"2016","unstructured":"Nam, R. K. et al. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence. Prostate 76, 869\u2013884 (2016).","journal-title":"Prostate"},{"key":"991_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86785-z","volume":"11","author":"MY Kim","year":"2021","unstructured":"Kim, M. Y. et al. Urinary exosomal microRNA profiling in intermediate-risk prostate cancer. Sci. Rep. 11, 7355 (2021).","journal-title":"Sci. Rep."},{"key":"991_CR173","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","volume":"67","author":"X Huang","year":"2015","unstructured":"Huang, X. et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur. Urol. 67, 33\u201341 (2015).","journal-title":"Eur. Urol."},{"key":"991_CR174","doi-asserted-by":"publisher","first-page":"101240","DOI":"10.1016\/j.xcrm.2023.101240","volume":"4","author":"W Tao","year":"2023","unstructured":"Tao, W. et al. A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: a multi-center study. Cell Rep. Med. 4, 101240 (2023).","journal-title":"Cell Rep. Med."},{"key":"991_CR175","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko, F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat. Rev. Genet. 19, 81\u201392 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"991_CR176","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.urolonc.2009.09.015","volume":"29","author":"G Sonpavde","year":"2011","unstructured":"Sonpavde, G. et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol. Oncol. 29, 682\u2013689 (2011).","journal-title":"Urol. Oncol."},{"key":"991_CR177","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clgc.2014.07.008","volume":"13","author":"R Singal","year":"2015","unstructured":"Singal, R. et al. Phase I\/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin. Genitourin. Cancer 13, 22\u201331 (2015).","journal-title":"Clin. Genitourin. Cancer"},{"key":"991_CR178","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1016\/j.cell.2023.05.028","volume":"186","author":"H Guo","year":"2023","unstructured":"Guo, H. et al. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell 186, 2765\u20132782 e2728 (2023).","journal-title":"Cell"},{"key":"991_CR179","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R. & Baylin, S. B. The emerging role of epigenetic therapeutics in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 75\u201390 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"991_CR180","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim, H. E. et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell 170, 142\u2013157.e19 (2017).","journal-title":"Cell"},{"key":"991_CR181","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004495","volume":"10","author":"D Papadatos-Pastos","year":"2022","unstructured":"Papadatos-Pastos, D. et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J. Immunother. Cancer 10, e004495 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"991_CR182","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-21-0581","volume":"21","author":"E Farah","year":"2022","unstructured":"Farah, E. et al. Targeting DNMTs to overcome enzalutamide resistance in prostate cancer. Mol. Cancer Ther. 21, 193\u2013205 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"991_CR183","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05037500 (2024)."},{"key":"991_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03709550 (2022)."},{"key":"991_CR185","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","volume":"52","author":"SY Park","year":"2020","unstructured":"Park, S. Y. & Kim, J. S. A short guide to histone deacetylases including recent progress on class II enzymes. Exp. Mol. Med. 52, 204\u2013212 (2020).","journal-title":"Exp. Mol. Med."},{"key":"991_CR186","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/0008-5472.CAN-08-2216","volume":"69","author":"DS Welsbie","year":"2009","unstructured":"Welsbie, D. S. et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 69, 958\u2013966 (2009).","journal-title":"Cancer Res."},{"key":"991_CR187","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/annonc\/mdp270","volume":"21","author":"LR Molife","year":"2010","unstructured":"Molife, L. R. et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann. Oncol. 21, 109\u2013113 (2010).","journal-title":"Ann. Oncol."},{"key":"991_CR188","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00280-013-2224-8","volume":"72","author":"DE Rathkopf","year":"2013","unstructured":"Rathkopf, D. E. et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 72, 537\u2013544 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"991_CR189","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10637-015-0252-4","volume":"33","author":"BJ Eigl","year":"2015","unstructured":"Eigl, B. J. et al. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Invest. New Drugs 33, 969\u2013976 (2015).","journal-title":"Invest. New Drugs"},{"key":"991_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04703920 (2024)."},{"key":"991_CR191","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06145633 (2024)."},{"key":"991_CR192","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","volume":"25","author":"AC Ferrari","year":"2019","unstructured":"Ferrari, A. C. et al. Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer. Clin. Cancer Res. 25, 52\u201363 (2019).","journal-title":"Clin. Cancer Res."},{"key":"991_CR193","doi-asserted-by":"publisher","first-page":"20853","DOI":"10.1074\/jbc.M000660200","volume":"275","author":"M Fu","year":"2000","unstructured":"Fu, M. et al. p300 and p300\/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 275, 20853\u201320860 (2000).","journal-title":"J. Biol. Chem."},{"key":"991_CR194","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/0008-5472.CAN-17-0314","volume":"77","author":"L Jin","year":"2017","unstructured":"Jin, L. et al. Therapeutic targeting of the CBP\/p300 bromodomain blocks the growth of castration-resistant prostate cancer. Cancer Res. 77, 5564\u20135575 (2017).","journal-title":"Cancer Res."},{"key":"991_CR195","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti, J. et al. Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov. 11, 1118\u20131137 (2021).","journal-title":"Cancer Discov."},{"key":"991_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03568656 (2024)."},{"key":"991_CR197","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/path.6280","volume":"263","author":"N Choo","year":"2024","unstructured":"Choo, N. et al. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer. J. Pathol. 263, 242\u2013256 (2024).","journal-title":"J. Pathol."},{"key":"991_CR198","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.1038\/s41388-021-01982-4","volume":"40","author":"SH Park","year":"2021","unstructured":"Park, S. H. et al. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene 40, 5788\u20135798 (2021).","journal-title":"Oncogene"},{"key":"991_CR199","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Molecular events in neuroendocrine prostate cancer development. Nat. Rev. Urol. 18, 581\u2013596 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"991_CR200","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/S1470-2045(20)30530-1","volume":"21","author":"R Groisberg","year":"2020","unstructured":"Groisberg, R. & Subbiah, V. EZH2 inhibition for epithelioid sarcoma and follicular lymphoma. Lancet Oncol. 21, 1388\u20131390 (2020).","journal-title":"Lancet Oncol."},{"issue":"(Suppl. 5)","key":"991_CR201","first-page":"S626","volume":"32","author":"AK Morgans","year":"2021","unstructured":"Morgans, A. K. et al. ESMO Congress abstracts. Genitourinary tumours, prostate. Ann. Oncol. 32 (Suppl. 5), S626\u2013S677 (2021).","journal-title":"Ann. Oncol."},{"key":"991_CR202","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04179864 (2024)."},{"key":"991_CR203","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1101\/gr.131508.111","volume":"22","author":"JC Zhao","year":"2012","unstructured":"Zhao, J. C. et al. Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res. 22, 322\u2013331 (2012).","journal-title":"Genome Res."},{"key":"991_CR204","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"K Xu","year":"2012","unstructured":"Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338, 1465\u20131469 (2012).","journal-title":"Science"},{"key":"991_CR205","doi-asserted-by":"publisher","unstructured":"Venkadakrishnan, V. B. et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Preprint at Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-3935288\/v2 (2024).","DOI":"10.21203\/rs.3.rs-3935288\/v2"},{"key":"991_CR206","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo, B., Tramontano, A., Pezone, A. & Migliaccio, A. LSD1: more than demethylation of histone lysine residues. Exp. Mol. Med. 52, 1936\u20131947 (2020).","journal-title":"Exp. Mol. Med."},{"key":"991_CR207","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1002\/cncr.34366","volume":"128","author":"A Hollebecque","year":"2022","unstructured":"Hollebecque, A. et al. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer 128, 3185\u20133195 (2022).","journal-title":"Cancer"},{"key":"991_CR208","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","volume":"8","author":"ZQ Wang","year":"2023","unstructured":"Wang, Z. Q. et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal. Transduct. Target. Ther. 8, 420 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"991_CR209","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","volume":"25","author":"SA Piha-Paul","year":"2019","unstructured":"Piha-Paul, S. A. et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors. Clin. Cancer Res. 25, 6309\u20136319 (2019).","journal-title":"Clin. Cancer Res."},{"key":"991_CR210","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","volume":"26","author":"G Falchook","year":"2020","unstructured":"Falchook, G. et al. Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies. Clin. Cancer Res. 26, 1247\u20131257 (2020).","journal-title":"Clin. Cancer Res."},{"key":"991_CR211","doi-asserted-by":"publisher","unstructured":"Attwell, S. et al. Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 76, https:\/\/doi.org\/10.1158\/1538-7445.AM2016-LB-207 (2016).","DOI":"10.1158\/1538-7445.AM2016-LB-207"},{"key":"991_CR212","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","volume":"26","author":"RR Aggarwal","year":"2020","unstructured":"Aggarwal, R. R. et al. A phase Ib\/IIa study of the Pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 26, 5338\u20135347 (2020).","journal-title":"Clin. Cancer Res."},{"key":"991_CR213","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G. & Postel-Vinay, S. Combining epigenetic drugs with other therapies for solid tumours \u2014 past lessons and future promise. Nat. Rev. Clin. Oncol. 17, 91\u2013107 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"991_CR214","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1080\/15592294.2021.1939477","volume":"17","author":"MB Pacheco","year":"2022","unstructured":"Pacheco, M. B., Camilo, V., Henrique, R. & Jeronimo, C. Epigenetic editing in prostate cancer: challenges and opportunities. Epigenetics 17, 564\u2013588 (2022).","journal-title":"Epigenetics"},{"key":"991_CR215","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","volume":"16","author":"A Ma","year":"2020","unstructured":"Ma, A. et al. Discovery of a first-in-class EZH2 selective degrader. Nat. Chem. Biol. 16, 214\u2013222 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"991_CR216","doi-asserted-by":"publisher","first-page":"10929","DOI":"10.1093\/nar\/gkac861","volume":"50","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. A cryptic transactivation domain of EZH2 binds AR and AR\u2019s splice variant, promoting oncogene activation and tumorous transformation. Nucleic Acids Res. 50, 10929\u201310946 (2022).","journal-title":"Nucleic Acids Res."},{"key":"991_CR217","doi-asserted-by":"publisher","first-page":"104972","DOI":"10.1016\/j.ebiom.2024.104972","volume":"100","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic. EBioMedicine 100, 104972 (2024).","journal-title":"EBioMedicine"},{"key":"991_CR218","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina, K. et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 113, 7124\u20137129 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"991_CR219","doi-asserted-by":"publisher","first-page":"105212","DOI":"10.1016\/j.ebiom.2024.105212","volume":"105","author":"D Zhang","year":"2024","unstructured":"Zhang, D. et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. EBioMedicine 105, 105212 (2024).","journal-title":"EBioMedicine"},{"key":"991_CR220","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05252390 (2024)."},{"key":"991_CR221","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin, J. et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J. Clin. Oncol. 36, 3007\u20133014 (2018).","journal-title":"J. Clin. Oncol."},{"key":"991_CR222","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02698176 (2021)."},{"key":"991_CR223","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03150056 (2021)."},{"key":"991_CR224","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04556617 (2022)."},{"key":"991_CR225","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02705469 (2017)."},{"key":"991_CR226","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04145375 (2024)."},{"key":"991_CR227","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04471974 (2024)."},{"key":"991_CR228","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04986423 (2024)."},{"key":"991_CR229","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05488548 (2024)."},{"key":"991_CR230","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00006019 (2013)."},{"key":"991_CR231","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00384839 (2018)."},{"key":"991_CR232","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03572387 (2024)."},{"key":"991_CR233","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04104776 (2024)."},{"key":"991_CR234","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04388852 (2024)."},{"key":"991_CR235","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03480646 (2021)."},{"key":"991_CR236","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03460977 (2024)."},{"key":"991_CR237","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03741712 (2021)."},{"key":"991_CR238","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04846478 (2024)."},{"key":"991_CR239","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05567679 (2023)."},{"key":"991_CR240","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06022757 (2024)."},{"key":"991_CR241","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00413075 (2015)."},{"key":"991_CR242","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00413322 (2015)."},{"key":"991_CR243","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00020579 (2012)."},{"key":"991_CR244","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03829930 (2021)."},{"key":"991_CR245","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00511576 (2015)."},{"key":"991_CR246","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00419536 (2010)."},{"key":"991_CR247","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00493766 (2020)."},{"key":"991_CR248","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00663832 (2020)."},{"key":"991_CR249","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00670553 (2017)."},{"key":"991_CR250","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00106301 (2019)."},{"key":"991_CR251","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00106418 (2019)."},{"key":"991_CR252","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00530907 (2015)."},{"key":"991_CR253","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00670046 (2018)."},{"key":"991_CR254","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00005634 (2013)."},{"key":"991_CR255","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00045006 (2013)."},{"key":"991_CR256","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00330161 (2014)."},{"key":"991_CR257","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00565227 (2016)."},{"key":"991_CR258","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00589472 (2017)."},{"key":"991_CR259","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01174199 (2022)."},{"key":"991_CR260","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04628988 (2023)."},{"key":"991_CR261","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05268666 (2023)."},{"key":"991_CR262","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04575766 (2023)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00991-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00991-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T12:13:58Z","timestamp":1751631238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00991-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":262,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00991-8","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"9 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}